Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

MLA

Ruzzo, Annamaria, et al. “Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.” Scientific Reports, vol. 10, no. 1, Jan. 2020, p. 1918. EBSCOhost, https://doi.org/10.1038/s41598-020-58486-6.

APA

Ruzzo, A., Graziano, F., Galli, F., Galli, F., Rulli, E., Lonardi, S., Ronzoni, M., Massidda, B., Zagonel, V., Pella, N., Mucciarini, C., Labianca, R., Ionta, M. T., Bagaloni, I., Veltri, E., Sozzi, P., Barni, S., Ricci, V., Foltran, L., … Magnani, M. (2020). Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. Scientific Reports, 10(1), 1918. https://doi.org/10.1038/s41598-020-58486-6

Chicago

Ruzzo, Annamaria, Francesco Graziano, Francesca Galli, Fabio Galli, Eliana Rulli, Sara Lonardi, Monica Ronzoni, et al. 2020. “Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.” Scientific Reports 10 (1): 1918. doi:10.1038/s41598-020-58486-6.